Product Pipeline

With medications in more than 4 therapeutic areas and over 15 products in just 5 years, Xeedia established itself as an industry leader. We’re dedicated to bringing the newest and most effective solutions and are always researching to create better and bigger ones.

The following table lists a selection of our product pipeline for the year

You-Q10 400mg

Supplement

Active

coenzyme Q10400Mg

Business unit line

General Health

Therapeutic Area

General Health

Dosage form

Soft Gelatin Capsules

Potential Indication

Status

Expected launch month

Supports Fertility & Body Energy

Under Development

Feb 2027

Omegal VIT

Supplement

Active

Fish oil500mg

Business unit line

General Health

Therapeutic Area

Child Care

Dosage form

Oral Suspension

Potential Indication

Status

Expected launch month

Supports Normal Brain Function

Under Development

Jan 2027

Contain

Omega 3 free fatty acid 300 Mg (54%-66%) Eicosapentanoic Acid EPA ( 9% – 11%) 50 mg Docosahexanoic Acid DHA (45 %-55% )250 mg Ascorbic acid (vitamin c)60 mg D-L Tocopheryl acetate13.33 Mg eq.to vitamin E 6 mg Niacin (vitamin b3 ) 8 mg Zinc citrate 7.32 mg eq.to zinc 2.5 mg Calcium D- pantothenate 3.2608 mg eq.to vitamin b5 3 mg Riboflavin sodium phosphate 0.8895 eq.to 0.7 mg Pyridoxine Hydrochloride 0.8508 mg eq.to vitamin b6 0.7 mg Thiamine hydrochloride 0.7 mg eq.to vitamin b1 0.55 mg Cholecalciferol oil 400 μg 1 MIU/I gm eq.to vitamin D3 400 iu Retinyl Palmitate [1.7 MIU/g] 392.157 μg eq.to vitamin A 200 μg Potassium iodide 52.324μgEQ.TO 40 μg Iodine Sodium selenate 35.893 μg eq.to selenium 15 μg Biotin 12.5 μg

Omegal Kids

Supplement

Active

Fish oil

Business unit line

General Health

Therapeutic Area

Child Care

Dosage form

Oral Syrup

Potential Indication

Status

Expected launch month

Maintains Normal Brain Function

Under Development

Jan 2027

Contain

2100 mg Eicosapentanoic Acid EPA( 16.5% – 19.8%)378 mg Docosahexanoic Acid DHA (10.8%-13.2% )252 mg D-L Alpha-tocopheryl acetate28.889 mg eq.to 13 mg Menaquinone-7 1100 µg [5 %] oil eq to vitamin K2 55 µg Retinol Palmitate 470.588 µg [1.7 MIU/gm] EQ .TO Vitamin A 800 IU Cholecalciferol 400 µg [1 MIU/1 gm] oil EQ .TO VITAMIN D3 400 IU

You-Mag

Supplement

Active

Magnesium Citrate

Business unit line

General Health

Therapeutic Area

General Health

Dosage form

Soft Gelatin Capsules

Potential Indication

Status

Expected launch month

Contributes to the Reduction of Fatigue & Supports Nervous System and Muscle Function

Under Development

Feb 2027

Contain

385 mg eq to Magnesium 62.23 mg Magnesium oxide 311.37 mg eq to Magnesium 187.77 mg

You-Q10 200mg

Supplement

Active

coenzyme Q10200Mg

Business unit line

General Health

Therapeutic Area

General Health

Dosage form

Soft Gelatin Capsules

Potential Indication

Status

Expected launch month

Supports Fertility & Body Energy

Under Development

Feb 2027

Omegal Mini

Supplement

Active

Tuna Fish Oil

Business unit line

General Health

Therapeutic Area

Child Care

Dosage form

Oral Liquid Drops

Potential Indication

Status

Expected launch month

Supports Healthy Growth & Development

Under Development

Apr 2027

Contain

400 mg DHA (22.5 %-27.5 %) 100 mg Cholecalciferol concentrate (oil form) Vitamin D3 min 1.0 MIU/g 0.4 mg eq to Vitamin D3 10 mcg DL tocopheryl acetate 5 mg eq to vitamin E 5 IU

Diclopro spray

Pharmaceutical

Active

diclofenac sodium4%

Business unit line

orthopedic

Therapeutic Area

ANTIRHEUMATICS NON-S PLN

Dosage form

cutaneous spray solution

Potential Indication

Status

Expected launch month

sprains - strains - low back pain - RA- OA

Under Development

Feb 2025

Diclopro Relax

Pharmaceutical

Active

methocarbamol500MG

diclofenac50MG

Business unit line

orthopedic

Therapeutic Area

MUSCLE RELAXANTS, CENTRAL

Dosage form

Film coated tablet

Potential Indication

Status

Expected launch month

Muscle relaxant - Muscle spasm

Under Development

Jul 2025

Diclopro syp

Pharmaceutical

Active

diclofenac potassium2mg/ml

Business unit line

orthopedic

Therapeutic Area

ANTIRHEUMATICS NON-S PLN

Dosage form

Suspention

Potential Indication

Status

Expected launch month

anti inflammatory - antipyretic - analgesic

Under Development

Jul 2025

Diclopro Amp

Pharmaceutical

Active

diclofenac sodium75MG/3ML

Business unit line

orthopedic

Therapeutic Area

ANTIRHEUMATICS NON-S PLN

Dosage form

solution for IM injection or IV infusion

Potential Indication

Status

Expected launch month

osteoarthritis - RA -Arthritis flare ups - Gout- Acute musculoskeletal disorders

Under Development

Sep 2025

Osvyrti

Pharmaceutical

Active

Denosumab60mg/ml

Business unit line

Orthopedic & Rheumatology

Therapeutic Area

Endocrinolgy/Metabolic Bone Diseases and Oncology/Supportive Cancer Care

Dosage form

Solution for Injection

Potential Indication

Status

Expected launch month

Osteoprosis

Under Development

Oct 2027

Linagliflozin Met 10/5/1000mg

Pharmaceutical

Active

Empagliflozin10mg

Business unit line

Cardiovascular Metabolic

Therapeutic Area

Endocrinology and Metabolic Diseases

Dosage form

Extended Release Film Coated Tablets

Potential Indication

Status

Expected launch month

Type 2 Diabetes

Under Development

Jul 2027

Contain

Linagliptin 5 mg Metformin 1000 mg

Linagliflozin Met 25/5/1000mg

Pharmaceutical

Active

EMPAGLIFLOZIN25mg

Business unit line

Cardiovascular Metabolic

Therapeutic Area

Endocrinology and Metabolic Diseases

Dosage form

Extended Release Film Coated Tablet

Potential Indication

Status

Expected launch month

Type 2 Diabetes

Under Development

Jul 2027

Contain

Linagliptin 5 mg METFORMIN HYDROCHLORIDE 1000 mg

Linagliflozin Met 12.5/2.5/1000 MG

Pharmaceutical

Active

Empagliflozin12.5mg

Business unit line

Cardiovascular Metabolic

Therapeutic Area

Endocrinolgy & Metabolic Diseases

Dosage form

Extended Release Film Coated Tablets

Potential Indication

Status

Expected launch month

Type 2 Diabetes

Under Development

Jul 2027

Contain

Linagliflozin 2.5 mg Metformin Hydrochloride 1000 mg

Sondelbay

Pharmaceutical

Active

Teriparatide0.25mg/ml

Business unit line

Oncolgy

Therapeutic Area

Endocrinology and Bone Metabolism

Dosage form

Solution for Injection

Potential Indication

Status

Expected launch month

Osteoprosis

Under Development

Oct 2027

Jubereq

Pharmaceutical

Active

Denosumab120mg/1.7ml

Business unit line

Oncology

Therapeutic Area

Endocrinology/Metabolic Bone Diseases and Oncology/Supportive Cancer Care

Dosage form

Solution for Injection

Potential Indication

Status

Expected launch month

Bone Metastases & Multiple Myeloma

Under Development

Oct 2027

Newsletter